Tabernero, J., Hoff, P. M., Shen, L., Ohtsu, A., Shah, M. A., Siddiqui, A., et al. (2020). End-of-study analysis from JACOB: A phase III study of pertuzumab (P) plus trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC). Annals of Oncology, 31, S900-S901. https://doi.org/10.1016/j.annonc.2020.08.1929